title: Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancer.
abstract: Cisplatin-based combinations are standard regimens in the treatment of advanced non-small cell lung cancer. Survival improvement has been achieved using this therapy. However, the high toxicity induced by cisplatin-based doublets urges the research of alternate treatments. Newest cytotoxic compounds yield a better efficacy-toxicity ratio. Platinum-free doublet regimens based on new drugs are expected to offer the patient an improved survival without decreasing his quality of life. Treatment-allocated time and period with high grade toxicity could be considered as wasted from the patient point of view. QUALY methods based on time without symptoms and toxicity allow the accurate evaluation of this end-point. This brief state-of-the-art deals with methodological statements highlighted by the first publications of randomized studies comparing non-platinum-based doublets with either single-drug chemotherapy or standard cisplatin-based doublets.
authors.affiliation: Montpellier University Academic Hospital, Unité d'Oncologie Thoracique, Hôpital Arnaud de Villeneuve, Avenue du doyen Giraud, 34295 Montpellier cedex 5, France. pujol@cyber-sante.org
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Pujol
authors.forename: Xavier
authors.initials: X
authors.lastname: Quantin
authors.forename: Didier
authors.initials: D
authors.lastname: Choma
authors.forename: William
authors.initials: W
authors.lastname: Jacot
authors.forename: Farid
authors.initials: F
authors.lastname: Khial
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011788:Quality of Life; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D001952:Bridged-Ring Compounds; D043823:Taxoids; D003841:Deoxycytidine; C080625:taxane; D014747:Vinblastine; D000077235:Vinorelbine; D000093542:Gemcitabine